Abstract

Ligand binding to the PTH1 receptor is described by a "two-site" model, in which the C-terminal portion of the ligand interacts with the N-terminal domain of the receptor (N interaction), and the N-terminal region of the ligand binds the juxtamembrane domain of the receptor (J interaction). Previous studies have not considered the dynamic nature of receptor conformation in ligand binding and receptor activation. In this study the ligand binding mechanism was compared for the G-protein-coupled (RG) and uncoupled (R) PTH1 receptor conformations. The two-site model was confirmed by demonstration of spatially distinct binding sites for PTH(3-34) and PTH(1-14): PTH(1-14), which binds predominantly to the J domain, only partially inhibited binding of 125I-PTH(3-34); and PTH(3-34), shown to bind predominantly to the N domain, only partially inhibited PTH(1-14)-stimulated cAMP accumulation. To assess the effect of R-G coupling, ligand binding to R was measured by displacement of 125I-PTH(3-34) with 30 microM guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) present, and binding to RG was measured by displacement of 125I-[MAP]PTHrP(1-36) (where MAP is model amphipathic peptide), a new radioligand that binds selectively to RG. Agonists bound with higher affinity to RG than R, whereas antagonists bound similarly to these states. The J interaction was responsible for enhanced agonist binding to RG: residues 1 and 2 were required for increased PTH(1-34) affinity for RG; residue 5 of MAP-PTHrP(1-36) was a determinant of R/RG binding selectivity, and PTH(1-14) bound selectively to RG. The N interaction was insensitive to R-G coupling; PTH(3-34) binding was GTPgammaS-insensitive. Finally, several observations suggest the receptor conformation is more "closed" at RG than R. At the R state, an open conformation is suggested by the simultaneous binding of PTH(1-14) and PTH(3-34). At RG PTH(1-14) better occluded binding of 125I-PTH(3-34) and agonist ligands bound pseudo-irreversibly, suggesting a more closed conformation of this receptor state. The results extend the two-site model to take into account R and RG conformations and suggest a model for differences of receptor conformation between these states.

Highlights

  • The parathyroid hormone 1 (PTH1)1 receptor is a cell-surface signal transducer for PTH and PTH-related protein (PTHrP)

  • Likewise the ligand (PTH or PTHrP) can be divided into two binding regions; the 15–34 portion is a determinant of receptor binding affinity [12, 16, 17], and the 1–14 portion is a determinant of receptor activation for stimulation of cAMP production (12, 18 –21). (The cAMP-stimulating activity and high affinity binding of PTH and PTHrP are retained within an N-terminal fragment of 34 residues [22].) These observations suggested a “two-site” mode of receptor-ligand interaction (Fig. 1), in which the C-terminal portion of the ligand interacts with the N domain of the receptor (N interaction), and the N-terminal ligand region binds to the J domain of the receptor (J interaction) [11,12,13, 19]

  • For type II G-protein-coupled receptors (GPCRs) a great deal is known regarding the orientation of ligand binding, but very little is known regarding how the two-site binding mechanism is affected by the conformational changes in the receptor that result from R-G interaction

Read more

Summary

EXPERIMENTAL PROCEDURES

Reagents and Peptides—The following peptides were purchased from Bachem (Torrance, CA) or Peninsula Laboratories (Belmont, CA): [Nle8,18,Tyr34]bPTH[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34]-amide, [Nle8,18,Tyr34]bPTH[3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34]-amide, [D-Trp12,Tyr34]bPTH[7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34]-amide, [Nle8,18,Tyr34]bPTH[7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34]-amide, and [Tyr36]PTHrP[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36]-amide. hPTH[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34] and bTIP39 were obtained from AnaSpec Inc. (San Jose, CA). bTIP[7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39] was obtained from Biomolecules Midwest (Waterloo, IL). [MAP22–31,Tyr36]PTHrP[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36]amide, [Ile5,MAP22–31,Tyr36]PTHrP[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36]-amide, [Ala3,10,12,Arg11] rPTH[1,2,3,4,5,6,7,8,9,10,11,12,13,14]-amide, and [Ala1,3,10,12,Arg11,19,Tyr34]hPTH[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34] were synthesized by the M. Data points in figures are presented as the mean Ϯ S.E. of triplicate measurements, and in some cases the error bars are enclosed within the symbol

RESULTS
19 Ϯ 7 12 Ϯ 8
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call